



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com


[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



Na_v1.7 Blocker 52 Item No. 34477

CAS Registry No.: 1211866-85-1
Formal Name: N-[2-methyl-3-[[4-[4-[[4-(trifluoromethoxy)phenyl]methoxy]-1-piperidinyl]-1,3,5-triazin-2-yl]amino]phenyl]-acetamide
Synonyms: TC-N 1752, Voltage-gated Sodium Channel 1.7
MF: C₂₅H₂₇F₃N₆O₃
FW: 516.5
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Na_v1.7 blocker 52 is supplied as a solid. A stock solution may be made by dissolving the Na_v1.7 blocker 52 in the solvent of choice, which should be purged with an inert gas. Na_v1.7 blocker 52 is soluble in the organic solvent DMSO at a concentration of approximately 30 mg/ml.

Description

Na_v1.7 blocker 52 is an inhibitor of voltage-gated sodium channel 1.7 (Na_v1.7; IC₅₀ = 0.17 μM).¹ It is selective for Na_v1.7 over human-ether-a-go-go (hERG), also known as K_v11.1, Na_v1.5, and Na_v1.8 (IC₅₀s = >10, 1.1, and 2.2 μM, respectively) but does inhibit Na_v1.3 and Na_v1.4 (IC₅₀s = 0.3 and 0.4 μM, respectively). Na_v1.7 blocker 52 (20 and 30 mg/kg) inhibits formalin-induced flinching in a rat model of persistent pain. It also increases the latency to paw withdrawal in a hot plate test in a mouse model of inflammatory pain induced by complete Freund's adjuvant (CFA).¹

References

1. Bregman, H., Berry, L., Buchanan, J.L., *et al.* Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain. *J. Med. Chem.* **54**(13), 4427-4445 (2011).
2. Matson, D.J., Hamamoto, D.T., Bregman, H., *et al.* Inhibition of inactive states of tetrodotoxin-sensitive sodium channels reduces spontaneous firing of C-fiber nociceptors and produces analgesia in formalin and complete Freund's adjuvant models of pain. *PLoS One* **10**(9), e0138140 (2015).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/23/2021

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM